•Life-saving medicines may elude millions of Nigeria – Report
For a Nigerian living with diabetes, cancer or another long-term illness, getting the right medicine can be a daily struggle. Beyond the fear of the disease itself, patients and their families must contend with the rising cost of treatment, irregular supplies and the uncertainty of whether newer, potentially more effective medicines will ever become affordable or available in the country.
For many, treatment is not simply a matter of visiting a hospital and collecting a prescription. It means making difficult choices between buying medicines, paying other household bills and meeting basic needs. Some patients are forced to reduce doses, delay treatment or depend on the support of relatives and charitable organisations.
The situation raises a troubling question as pharmaceutical companies develop new medicines for diseases affecting millions of people especially in Nigeria and other low-income countries
The 2026 Access to Medicine Index report examines the efforts of 20 major pharmaceutical companies to make medicines available and affordable in low- and middle-income countries. While the report records some progress, it warns that access remains uneven, with poorer countries at risk of being left behind.
For Nigeria, where the cost of healthcare remains a major burden for many households, the findings underline the need for pharmaceutical companies, governments and local manufacturers to do more to ensure that medical breakthroughs reach the people who need them.
New medicines and affordability
The development of new medicines offers hope to people living with serious and chronic illnesses. But that hope means little if patients cannot afford the treatment or if the products do not reach their countries.
According to the Index, pharmaceutical companies now have plans to improve access for 69 per cent of medicines in the later stages of development. This is more than three times the level recorded in 2018.
However, the report exposes a major gap between having plans and making medicines available where they are needed. Only 36 per cent of the products assessed had plans specifically addressing access in low-income countries. This compares with 80 per cent for lower-middle-income countries and 85 per cent for upper-middle-income countries.
The difference is significant for countries such as Nigeria, where many patients pay directly for healthcare and can struggle to meet the cost of treatment.
According to experts, an estimated 589 million adults worldwide are living with the disease, with 81 per cent of them in low- and middle-income countries.
Yet, the report finds that plans for making new diabetes treatments available tend to concentrate on markets considered more commercially attractive. Poorer countries, including those with substantial healthcare needs, receive less attention.
The findings also raise questions about access to newer medicines used in managing type 2 diabetes, including GLP-1 treatments. Although some companies have introduced lower-priced brands in selected countries, the Index did not identify such strategies specifically for Nigeria.
For Nigerian patients, this means that the arrival of new treatments does not automatically translate into access. Without deliberate plans on pricing, supply and distribution, many could remain beyond the reach of ordinary households.
Insulin: Patients can’t afford interruptions
For people living with type 1 diabetes, access to insulin is not optional. It is essential for survival. A disruption in supply or inability to pay for treatment can have serious consequences.
The Index further raised concern over manufacturers reducing production of some older insulin products and formulations. Such changes could disrupt supplies and leave patients with fewer choices, potentially forcing some to switch to newer or more expensive alternatives.
This is particularly worrying for patients in countries where access to affordable insulin is already difficult.
The report also disclosed that Novo Nordisk’s Access to Insulin Commitment, which places a ceiling of $3 per vial of human insulin in selected low- and middle-income public-sector markets, represents one effort to address affordability. However, the report notes that the commitment does not cover every discontinued formulation or guarantee uninterrupted supplies.
A medicine may be offered at a lower price, but patients still need to find it consistently in hospitals and pharmacies. Across Africa, some programmes have helped children and young people living with diabetes obtain insulin, monitoring supplies and medical support.
Other News
Novo Nordisk’s Changing Diabetes in Children programme in Uganda, for instance, expanded from about 200 young people in 2009 to around 4,000 in 2025.
Eli Lilly’s Life for a Child programme also provides insulin, monitoring supplies, medical care and education to children and young people, with its age limit extended from 26 to 30.
These initiatives demonstrate the difference that support can make. But the report cautions that donations and charitable programmes cannot provide a lasting solution for people who need treatment throughout their lives.
For Nigeria, patients need dependable access to affordable insulin through sustainable health systems, not assistance that may be limited by programme duration or funding.
Africa’s experience offers lessons for Nigeria
The access challenge is not peculiar to Nigeria. Across Africa, patients face difficulties obtaining medicines for cancer, sickle cell disease, malaria and other conditions.
The Index found that only 19 per cent of the cancer medicines assessed had access plans covering low-income countries. This leaves many patients at risk of being excluded from advances in treatment.
However, some initiatives on the continent show what can be achieved when pharmaceutical companies, governments and local institutions work together.
The report also highlights efforts involving medicines for sickle cell disease and malaria, as well as research into long-acting HIV prevention. These developments offer hope, but they also raise the need to ensure that African countries are included in plans for supplying new medicines once they become available.
Nigeria’s position in this conversation is especially important because of its population and healthcare needs. The country cannot afford to remain only a market for imported medicines or a place where patients wait for products developed elsewhere.
The report also points to the importance of local production and technology transfer. Building stronger manufacturing capacity in Africa could improve supply security, reduce dependence on imports and support more affordable access.
And for Nigeria, this would require investment in local pharmaceutical manufacturers, stronger regulatory systems, reliable procurement arrangements and policies that encourage long-term partnerships.
Companies must show results, not promises
The Index makes clear that commitments alone are not enough. Pharmaceutical companies must demonstrate that their efforts are reaching patients and improving access.
This means providing clear information on the medicines being supplied, the countries covered, the number of people reached and whether the products are affordable. It also means setting measurable targets and reporting progress.
The report notes that some companies have linked executive pay to patient access and reach, while others have made commitments through sustainability-linked financing. Such measures could help make access to medicines a more central part of business decisions.
Nigeria’s experience with the changing presence of multinational drug companies also highlights the importance of a stable operating environment. GSK and Sanofi announced in 2023 that they would end direct commercial operations in Nigeria and move to third-party distribution arrangements, citing challenges including foreign exchange instability and high operating costs.
The development reinforces the need for policies that support the continued availability of essential medicines while encouraging local production and reliable distribution.
Ultimately, the test of pharmaceutical innovation should not be how many new medicines companies develop, but whether patients can obtain them when they need them.
For Nigerians living with diabetes, cancer and other serious illnesses, access is not an abstract policy debate. It is the difference between continuing treatment and going without it.
The 2026 Access to Medicine Index presents a challenge to drug companies and governments: ensure that the benefits of medical advances do not stop at the doors of wealthier markets but reach patients across Nigeria and the rest of Africa.

Follow Us on Google
